The US Food and Drug Administration approved a supplement to an abbreviated new drug application for adrenaline (epinephrine) from the manufacturer Gland.
This is a generic supply approval, concerning a manufacturer of an already-marketed drug rather than a new product, indication or safety signal. Adrenaline's role in anaphylaxis and cardiac arrest is unchanged, as are its dosing and routes.
For emergency practice, including in India where adrenaline is widely available generically, the effect is on supply and manufacturing rather than on how the drug is used. It is recorded here only to complete the regulatory sweep.
- The FDA approved a supplement to a generic adrenaline application (Gland).
- Adrenaline is first-line for anaphylaxis and used in cardiac arrest.
- The approval concerns supply, not a new indication or formulation.
- Dosing and routes are unchanged by an administrative approval.
- For most clinicians the effect is on availability, not practice.
Why it matters
It is a supply-side regulatory action, easily mistaken for news that changes how adrenaline is used.
Don't overread it
A generic manufacturing supplement is an administrative approval, not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for emergency & critical care, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free